Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.78
-1.3%
$0.76
$0.38
$115.57
$9.08M0.711.49 million shs47,671 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.70
-2.9%
$1.41
$0.47
$4.25
$8.65M1.41413,845 shs48,801 shs
Novan, Inc. stock logo
NOVN
Novan
$0.00
$0.08
$3.33
$2.64M-0.06602,421 shs7.19 million shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs31,800 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
+1.33%+9.02%+2.92%+3.35%-98.53%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-4.37%+4.79%-25.85%+91.47%+842.38%
Novan, Inc. stock logo
NOVN
Novan
0.00%0.00%0.00%0.00%0.00%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%-75.00%-75.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.78
-1.3%
$0.76
$0.38
$115.57
$9.08M0.711.49 million shs47,671 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.70
-2.9%
$1.41
$0.47
$4.25
$8.65M1.41413,845 shs48,801 shs
Novan, Inc. stock logo
NOVN
Novan
$0.00
$0.08
$3.33
$2.64M-0.06602,421 shs7.19 million shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs31,800 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
+1.33%+9.02%+2.92%+3.35%-98.53%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-4.37%+4.79%-25.85%+91.47%+842.38%
Novan, Inc. stock logo
NOVN
Novan
0.00%0.00%0.00%0.00%0.00%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%-75.00%-75.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
3.00
Buy$360.0046,053.85% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
Novan, Inc. stock logo
NOVN
Novan
0.00
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
Novan, Inc. stock logo
NOVN
Novan
$24.71M0.00N/AN/A$0.19 per share0.00
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M-$6.084.33N/AN/AN/AN/A-994.63%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.89N/AN/AN/A-123.06%-94.28%N/A
Novan, Inc. stock logo
NOVN
Novan
-$31.31M-$1.32N/AN/AN/A-128.61%-700.28%-39.58%N/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Novan, Inc. stock logo
NOVN
Novan
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
Novan, Inc. stock logo
NOVN
Novan
N/A
0.74
0.72
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Novan, Inc. stock logo
NOVN
Novan
14.51%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
0.86%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Novan, Inc. stock logo
NOVN
Novan
1.30%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
511.64 million74.37 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
Novan, Inc. stock logo
NOVN
Novan
9028.02 million27.65 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
ObsEva (NASDAQ: OBSV)
ObsEva Annual Report 2022 - Marketscreener.com
ObsEva Annual Report 2022 - Yahoo Finance
ObsEva Annual Report 2022 - Benzinga
ObsEva Annual Report 2022 - EIN News

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.78 -0.01 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$0.78 -0.01 (-0.64%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$1.70 -0.05 (-2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 +0.03 (+1.47%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Novan stock logo

Novan NASDAQ:NOVN

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.